Skip to main
OKUR
OKUR logo

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc showed a slightly improved financial performance for 2Q25, with a net loss of $1.14 per share compared to an estimated loss of $1.22 per share, indicating better-than-expected management of expenses. The positive results from the clinical trials of its candidate OKI-219, which demonstrated high tolerability across all dose levels without significant adverse events, further support the company's strong position in the biopharmaceutical sector. The company's focus on developing precision medicines targeting underserved cancer therapies positions it well for potential future growth and success in the market.

Bears say

OnKure Therapeutics is projected to incur a significant net loss of $4.56 per share for the full year 2025, a slight improvement from the previous estimate of $4.75 per share. The company faces considerable risks, including potential negative clinical outcomes with its lead asset, OKI-219, and the possibility of delays in advancing its pipeline candidates into critical regulatory programs. Additionally, challenges related to timely regulatory approvals and increasing competition from other mutant-selective PI3Kα inhibitors further contribute to a negative outlook on the stock's performance.

OKUR has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 4 analysts, OKUR has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.